CLOV vs RPRX · rev $1.37B vs P/E 15, rev $2.26B
Clover Health Investments Corp (CLOV) versus Royalty Pharma Plc (RPRX) — a side-by-side from cached financials, not a winner call.
Clover Health Investments Corp (CLOV) is a healthcare plans company listed on US.
Royalty Pharma Plc (RPRX) is a biotechnology company listed on US.
Latest reported CLOV revenue for 2024-12-31 was $1.37B. Net income was -$43.0M. Revenue was up 8.8% from 2023-12-31 to 2024-12-31. CLOV currently screens at market cap $1.55B.
Latest reported RPRX revenue for 2024-12-31 was $2.26B. Net income was $1.33B. Revenue was down 3.9% from 2023-12-31 to 2024-12-31. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
CLOV currently screens at market cap $1.55B. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
Not investment advice. Open the CLOV and RPRX stock pages for the full models.
Not investment advice.